Skip to main content
Glycorex Transplantation AB logo

Glycorex Transplantation AB — Investor Relations & Filings

Ticker · GTAB ISIN · SE0000524530 LEI · 549300BFHBYZ3X96EP25 NGM Manufacturing
Open in API
Filings indexed 98 across all filing types
Latest filing 2020-10-23 Regulatory Filings
Country SE Sweden
Listing NGM GTAB

About Glycorex Transplantation AB

https://glycorex.com/

Glycorex Transplantation AB is a medical technology company that has developed a proprietary technology platform for the specific removal of antibodies from blood. The technology is based on biologically active carbohydrates for extracorporeal blood treatment. Its flagship product, Glycosorb® ABO, is a single-use medical device that enables organ transplantation across the blood group barrier, primarily for kidney, liver, heart, and stem cell transplants. Used clinically since 2001, the product has facilitated over 6,000 ABO-incompatible transplants with documented long-term results comparable to blood group compatible procedures. The company is leveraging its core technology to expand into new applications, including a product for creating universal blood plasma for transfusions and developing novel treatments for autoimmune diseases, with an initial focus on rheumatoid arthritis.

Recent filings

Filing Released Lang Actions
Glycorex Transplantation (GTAB B): Tillväxtmöjligheter för Glycorex – VD uppdatering
Regulatory Filings Classification · 85% confidence The document is a CEO update from Glycorex Transplantation, detailing growth strategies, product updates, and a potential listing change. It is under 5,000 characters and functions as a corporate communication/announcement rather than a formal financial report or regulatory filing. Given the content focuses on management's strategic outlook and business updates, it fits best as a general regulatory announcement (RNS) as it does not meet the criteria for a full management report (MDA) or investor presentation (IP).
2020-10-23 Swedish
Glycorex Transplantation (GTAB B): Sluter avtal med distributör i Turkiet. Uppdatering försäljning Glycosorb®-ABO
Regulatory Filings Classification · 90% confidence The document is a press release from Glycorex Transplantation AB announcing a new distribution agreement in Turkey and providing an update on sales performance for the third quarter. It includes specific financial commentary and market potential estimates but is not a formal quarterly report (IR) or an earnings release (ER) in the standard sense of a financial statement filing. It is a corporate announcement regarding business operations and market expansion, which falls under the 'Regulatory Filings' (RNS) category as it is a mandatory disclosure under the EU Market Abuse Regulation.
2020-10-02 Swedish
Interim / Quarterly Report 2020
Interim / Quarterly Report Classification · 100% confidence The document is a 'Delårsrapport' (Interim Report) for Glycorex Transplantation AB for the second quarter and first half of 2020. It contains detailed financial statements (income statement, balance sheet, cash flow), management commentary, and operational updates. It is not a mere announcement (RPA) as it contains the full financial data and analysis for the period. Therefore, it is classified as an Interim/Quarterly Report. H1 2020
2020-08-21 Swedish
Glycorex Transplantation (GTAB B): Pontus Nobréus utsedd till ny VD
Board/Management Information Classification · 100% confidence The document is an official announcement from Glycorex Transplantation AB regarding the appointment of a new CEO, Pontus Nobréus, to replace the current CEO, Johan Nilsson. This falls directly under the category of management changes, which is defined as 'Board/Management Information'.
2020-08-03 Swedish
Glycorex Transplantation (GTAB B): Ett nytt potentiellt användningsområde av bolagets UBP-produkt
Regulatory Filings Classification · 95% confidence The document is a press release from Glycorex Transplantation AB announcing promising initial results for a new application of their UBP product. It is a corporate announcement regarding business development and research progress, not a financial report, proxy, or governance document. As it does not fit into specific categories like M&A, dividends, or director dealings, it falls under the general regulatory announcement category.
2020-06-25 Swedish
Glycorex Transplantation (GTAB B): Bolaget påbörjar nästa steg i reumatoid artrit-projektet
Regulatory Filings Classification · 95% confidence The document is a press release from Glycorex Transplantation AB announcing the commencement of biocompatibility studies for their rheumatoid arthritis product. It provides business updates, market potential analysis, and company background. It does not fit into specific financial reporting categories like 10-K, IR, or ER, nor is it a report publication announcement. As it is a general corporate announcement regarding business operations and regulatory progress, it falls under the 'Regulatory Filings' (RNS) category.
2020-06-18 Swedish

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.